RIO DE JANEIRO, BRAZIL – According to Pluristem Therapeutics Inc., an Israeli regenerative medicine group, all patients were in the ICU with Covid-19, on ventilators, and suffering from acute respiratory syndrome. After the tests, which ran for a week, all improved and survived.
The treatment in question uses placenta, and is cell-based. Four out of the seven patients showed considerable improvement in their condition, considered severe, while three others were able to be taken off ventilators.
Four of the study subjects were in the so-called risk group, with comorbidities such as cardiovascular disease and renal failure. Nevertheless, they presented satisfactory results.
The therapy uses PLX cells, which, due to their immunological properties, would help the system to regulate and reverse the effects of pneumonia.
The company will now seek permission to conduct regular clinical trials in several countries and ultimately adopt a protocol for treating the infection caused by the novel coronavirus.